Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 25.93% decrease from the previous average price target of $13.50.

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light...